Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant <i>TP53</i> or Wild-Type <i>CTNNB1</i> Gene

Hepatocellular carcinoma (HCC) is an aggressive and chemoresistant cancer type. The development of novel therapeutic strategies is still urgently needed. Personalized or precision medicine is a new trend in cancer therapy, which treats cancer patients with specific genetic alterations. In this study...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jiunn-Chang Lin, Tsang-Pai Liu, Vivin Andriani, Muhammad Athoillah, Chih-Yang Wang, Pei-Ming Yang
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	bioinformatics hepatocellular carcinoma precision medicine taxanes Medicine R
Acceso en línea:	https://doaj.org/article/a76810d2876f4db1b3065310518cb5d6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a76810d2876f4db1b3065310518cb5d6
record_format	dspace
spelling	oai:doaj.org-article:a76810d2876f4db1b3065310518cb5d62021-11-25T18:07:57ZBioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant <i>TP53</i> or Wild-Type <i>CTNNB1</i> Gene10.3390/jpm111111992075-4426https://doaj.org/article/a76810d2876f4db1b3065310518cb5d62021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1199https://doaj.org/toc/2075-4426Hepatocellular carcinoma (HCC) is an aggressive and chemoresistant cancer type. The development of novel therapeutic strategies is still urgently needed. Personalized or precision medicine is a new trend in cancer therapy, which treats cancer patients with specific genetic alterations. In this study, a gene signature was identified from the transcriptome of HCC patients, which was correlated with the patients’ poorer prognoses. This gene signature is functionally related to mitotic cell cycle regulation, and its higher or lower expression is linked to the mutation in tumor protein p53 (<i>TP53</i>) or catenin beta 1 (<i>CTNNB1</i>), respectively. Gene–drug association analysis indicated that the taxanes, such as the clinically approved anticancer drug paclitaxel, are potential drugs targeting this mitotic gene signature. Accordingly, HCC cell lines harboring mutant <i>TP53</i> or wild-type <i>CTNNB1</i> genes are more sensitive to paclitaxel treatment. Therefore, our results imply that HCC patients with mutant <i>TP53</i> or wild-type <i>CTNNB1</i> genes may benefit from the paclitaxel therapy.Jiunn-Chang LinTsang-Pai LiuVivin AndrianiMuhammad AthoillahChih-Yang WangPei-Ming YangMDPI AGarticlebioinformaticshepatocellular carcinomaprecision medicinetaxanesMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1199, p 1199 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	bioinformatics hepatocellular carcinoma precision medicine taxanes Medicine R
spellingShingle	bioinformatics hepatocellular carcinoma precision medicine taxanes Medicine R Jiunn-Chang Lin Tsang-Pai Liu Vivin Andriani Muhammad Athoillah Chih-Yang Wang Pei-Ming Yang Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant <i>TP53</i> or Wild-Type <i>CTNNB1</i> Gene
description	Hepatocellular carcinoma (HCC) is an aggressive and chemoresistant cancer type. The development of novel therapeutic strategies is still urgently needed. Personalized or precision medicine is a new trend in cancer therapy, which treats cancer patients with specific genetic alterations. In this study, a gene signature was identified from the transcriptome of HCC patients, which was correlated with the patients’ poorer prognoses. This gene signature is functionally related to mitotic cell cycle regulation, and its higher or lower expression is linked to the mutation in tumor protein p53 (<i>TP53</i>) or catenin beta 1 (<i>CTNNB1</i>), respectively. Gene–drug association analysis indicated that the taxanes, such as the clinically approved anticancer drug paclitaxel, are potential drugs targeting this mitotic gene signature. Accordingly, HCC cell lines harboring mutant <i>TP53</i> or wild-type <i>CTNNB1</i> genes are more sensitive to paclitaxel treatment. Therefore, our results imply that HCC patients with mutant <i>TP53</i> or wild-type <i>CTNNB1</i> genes may benefit from the paclitaxel therapy.
format	article
author	Jiunn-Chang Lin Tsang-Pai Liu Vivin Andriani Muhammad Athoillah Chih-Yang Wang Pei-Ming Yang
author_facet	Jiunn-Chang Lin Tsang-Pai Liu Vivin Andriani Muhammad Athoillah Chih-Yang Wang Pei-Ming Yang
author_sort	Jiunn-Chang Lin
title	Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant <i>TP53</i> or Wild-Type <i>CTNNB1</i> Gene
title_short	Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant <i>TP53</i> or Wild-Type <i>CTNNB1</i> Gene
title_full	Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant <i>TP53</i> or Wild-Type <i>CTNNB1</i> Gene
title_fullStr	Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant <i>TP53</i> or Wild-Type <i>CTNNB1</i> Gene
title_full_unstemmed	Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant <i>TP53</i> or Wild-Type <i>CTNNB1</i> Gene
title_sort	bioinformatics analysis identifies precision treatment with paclitaxel for hepatocellular carcinoma patients harboring mutant <i>tp53</i> or wild-type <i>ctnnb1</i> gene
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a76810d2876f4db1b3065310518cb5d6
work_keys_str_mv	AT jiunnchanglin bioinformaticsanalysisidentifiesprecisiontreatmentwithpaclitaxelforhepatocellularcarcinomapatientsharboringmutantitp53iorwildtypeictnnb1igene AT tsangpailiu bioinformaticsanalysisidentifiesprecisiontreatmentwithpaclitaxelforhepatocellularcarcinomapatientsharboringmutantitp53iorwildtypeictnnb1igene AT vivinandriani bioinformaticsanalysisidentifiesprecisiontreatmentwithpaclitaxelforhepatocellularcarcinomapatientsharboringmutantitp53iorwildtypeictnnb1igene AT muhammadathoillah bioinformaticsanalysisidentifiesprecisiontreatmentwithpaclitaxelforhepatocellularcarcinomapatientsharboringmutantitp53iorwildtypeictnnb1igene AT chihyangwang bioinformaticsanalysisidentifiesprecisiontreatmentwithpaclitaxelforhepatocellularcarcinomapatientsharboringmutantitp53iorwildtypeictnnb1igene AT peimingyang bioinformaticsanalysisidentifiesprecisiontreatmentwithpaclitaxelforhepatocellularcarcinomapatientsharboringmutantitp53iorwildtypeictnnb1igene
_version_	1718411577200214016

Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant <i>TP53</i> or Wild-Type <i>CTNNB1</i> Gene

Ejemplares similares